Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/10417
Title: Novel 2 '-alkoxymethyl substituted klavuzon derivatives as inhibitors of Topo I and CRM1
Authors: Çetinkaya, Hakkı
Yıldız, Mehmet Salih
Kutluer, Meltem
Alkan, Aylin
Otaş, Hasan Ozan
Çağır, Ali
Keywords: Klavuzon
CRM1
Topoisomerase I
Pancreatic cancer
Hepatocellular carcinoma
3D spheroid
Anticancer agent
Issue Date: 2020
Publisher: Academic Press Inc.
Abstract: In this work, 2'-alkoxymethyl substituted klavuzon derivatives were prepared starting from 2-methyl-1-naphthoic acid in eight steps. Anticancer potencies of the synthesized compounds were evaluated by performing MTT cell viability test over cancerous and healthy pancreatic cell lines, along with CRM1 inhibitory properties in HeLa cells by immunostaining and Topo I inhibition properties by supercoiled DNA relaxation assay. Their cytotoxic activities were also presented in hepatocellular carcinoma cells (HuH-7) derived 3D spheroids. Among the tested klavuzon derivatives, isobutoxymethyl substituted klavuzon showed the highest selectivity of cytotoxic activity against pancreatic cancer cell line. They showed potent Topo I inhibition while their CRM1 inhibitory properties somehow diminished compared to 4'-alkylsubstituted klavuzons. The most cytotoxic 2'-methoxymethyl derivative inhibited the growth of the spheroids derived from HuH-7 cell lines and PI staining exhibited time and concentration dependent cell death in 3D spheroids.
Description: PubMed: 32890988
URI: https://doi.org/10.1016/j.bioorg.2020.104162
https://hdl.handle.net/10417
ISSN: 0045-2068
1090-2120
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record

CORE Recommender

Page view(s)

22
checked on Dec 9, 2021

Google ScholarTM

Check

Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.